Screener
NeoGenomics NEO Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by NeoGenomics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001077183-26-000059
| Line item | (unaudited)June 30, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders’ equity | ||
| Common stock, $0.001 par value, (250,000,000 shares authorized; 130,301,168 and 128,989,152 shares issued, respectively; 127,917,946 and 128,989,152 shares outstanding, respectively) | $130 | $129 |
| Treasury stock, at cost, (2,383,222 and 0 shares, respectively) (Note 7) | (25,000) | — |
| Additional paid-in capital | 1,259,272 | 1,270,235 |
| Accumulated other comprehensive income | 4 | 4 |
| Accumulated deficit | (448,674) | (433,806) |
| Total stockholders' equity | $785,732 | $836,562 |
| Total liabilities and stockholders’ equity | $1,352,243 | $1,359,830 |
Item 1. Financial Statements (unaudited)
FAQ
- What is NeoGenomics's total liabilities & equity?
- NeoGenomics (NEO) reported total liabilities & equity of $1.35B in Q2 2026.
- How has NeoGenomics's total liabilities & equity changed year-over-year?
- NeoGenomics's total liabilities & equity decreased by 3.0% year-over-year, from $1.39B to $1.35B.
- What is the long-term trend for NeoGenomics's total liabilities & equity?
- Over 5 years (2020 to 2025), NeoGenomics's total liabilities & equity has grown at a 6.6% compound annual growth rate (CAGR), from $988.33M to $1.36B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about NeoGenomics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude